T Cell Repertoire Analysis of Immune Mediated Skin Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00368784|
Recruitment Status : Recruiting
First Posted : August 25, 2006
Last Update Posted : February 8, 2019
|Condition or disease|
|Psoriasis Mycosis Fungoides|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||T Cell Repertoire Analysis of Immune Mediated Skin Diseases|
|Study Start Date :||January 2007|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||October 2019|
Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
- Peripheral blood will be collected from adults ages 18-85. [ Time Frame: 2 Years ]These samples will then be used for PCR analysis and T cell cloning.
- T cell repertoire [ Time Frame: 2 Years ]characterizing the T cell repertoire of individuals with immune mediated skin disease (e.g. psoriasis and mycosis fungoides).
Biospecimen Retention: Samples With DNA
Fifteen tablespoons of blood will be collected prior to the initiation of a treatment and again after the patient shows a clinical response to a treatment. The time between blood draws will be no less than 3 months. There will be no more than two blood draws per patient.
Blood samples will be used to determine the patient's HLA haplotype via PCR and DNA sequencing. After the patient's haplotype has been established the activated T cell repertoire will be analyzed for clonal expansions. Clonal expansions in the T cell repertoire will be determined by immunoscope analysis, which is a PCR based technique.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00368784
|Contact: Emanaual Maverakis, M.D.||email@example.com|
|Contact: Victoria Wellsfirstname.lastname@example.org|
|United States, California|
|University of California, Davis Department of Dermatology||Recruiting|
|Sacramento, California, United States, 95816|
|Contact: Emanual Maverakis, M.D. 916-734-1267 email@example.com|
|Contact: Victoria Wells 916-734-1267 firstname.lastname@example.org|
|Principal Investigator: Emanual Maverakis, M.D.|
|Principal Investigator:||Emanual Maverakis, M.D.||University of California, Davis|